Long-term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulphonylureas.
Seventeen non-insulin-dependent diabetics poorly controlled by diet and sulphonylurea drugs took part in a long-term (20-52 weeks) trial of the effect of an alpha-glucosidase inhibitor (acarbose 100 mg thrice daily) on postprandial glycaemic and gastro-entero-pancreatic hormone responses. Patients were assessed before, during, and after the trial period with identical 2.2 MJ mixed test meals plus placebo or acarbose 100 mg, and sulphonylurea therapy was continued throughout. Acarbose administration reduced the integrated postprandial plasma responses of glucose to 58 +/- 10% (mean +/- SEM, p less than 0.001), insulin to 61 +/- 10% (p less than 0.01) and gastric inhibitory polypeptide to 45 +/- 8% (p less than 0.001) of control values, increased the enteroglucagon response to 152 +/- 26% (p less than 0.001) of control and slightly prolonged the postprandial release of motilin. Recorded glycosuria was significantly (p less than 0.01) reduced throughout the treatment period. The effects of acarbose on postprandial glycaemic and endocrine responses remained approximately constant throughout the trial period, and responses returned to pre-treatment values within 2 days of stopping treatment.
D020909:Acarbose; D000293:Adolescent; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005215:Fasting; D005260:Female; D005500:Follow-Up Studies; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D005768:Gastrointestinal Hormones / Q000097:blood*; D004763:Glucagon-Like Peptides / Q000097:blood; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009037:Motilin / Q000097:blood; D010187:Pancreatic Hormones / Q000097:blood*; D010349:Patient Compliance; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013997:Time Factors; D014312:Trisaccharides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
D001786:Blood Glucose; D005768:Gastrointestinal Hormones; D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin; D008055:Lipids; D010187:Pancreatic Hormones; D013453:Sulfonylurea Compounds; D014312:Trisaccharides; D009037:Motilin; D005749:Gastric Inhibitory Polypeptide; D004763:Glucagon-Like Peptides; D020909:Acarbose